Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06053411
EARLY_PHASE1

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

Sponsor: Washington State University

View on ClinicalTrials.gov

Summary

The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.

Official title: Pilot Study to Assess the Contribution of UGT2B17 and Associated Genetic Polymorphisms on the Pharmacokinetics of Diclofenac Alone and Upon Co-administration With Curcumin

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-03-01

Completion Date

2026-08-18

Last Updated

2024-11-18

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Diclofenac

25 mg capsule

DIETARY_SUPPLEMENT

curcumin

2,000 mg tablet

Locations (1)

Washington State University College of Pharmacy and Pharmaceutical Sciences

Spokane, Washington, United States